Record Performance Drives Strong Future Outlook
Wix has announced its Q1 2024 financial results, showcasing impressive performance and setting the stage for substantial revenue growth in the coming year. The company reported a total revenue of $419.8 million for the first quarter, reflecting a robust 12% year-over-year (y/y) increase. This growth is expected to accelerate further in 2025, with confidence high that Wix will significantly exceed the Rule of 40, a key performance metric for software companies.
Key highlights from Q1 2024 include:
- Creative Subscriptions: Revenue reached $304.3 million, a 9% y/y increase, with an annual recurring revenue (ARR) of $1.24 billion, up 10% y/y.
- Business Solutions: Revenue surged by 20% y/y to $115.5 million, with transaction revenue contributing $49.5 million, up 17% y/y.
- Partners Revenue: Grew substantially by 33% y/y to $138.4 million.
Total bookings in Q1 2024 were $457.3 million, marking a 10% y/y increase. Notably, Business Solutions bookings grew by 21% y/y to $122.6 million. The company’s gross margin remained solid, with a GAAP basis margin of 67% and a non-GAAP margin of 68%.
Financially, Wix reported a GAAP net income of $24.0 million ($0.43 per basic share) and a non-GAAP net income of $77.3 million ($1.38 per basic share). The company generated $113.8 million in net cash from operating activities, with free cash flow reaching $105.7 million.
Wix’s strategic initiatives and product offerings have positioned it well for continued growth. The company has raised its full-year bookings outlook to $1,796-$1,826 million, expecting 12-14% y/y growth. This increase is driven by stronger-than-expected performance and higher customer retention following a recent price increase.
The outlook for the second half of 2024 includes anticipated bookings growth acceleration to 16%, propelled by AI products enhancing conversion rates and the ramp-up of Wix Studio. As Wix continues to innovate and expand its market reach, it is well-poised for a strong financial trajectory heading into 2025.
You might like this article:Biotech and Tech Stocks Surge Amid Promising Developments
